Explore private publisher requirements →Peptide topic directory / Modified GRF 1-29 (“CJC-1295 without DAC”)
Publisher-review information
Modified GRF 1-29 Affiliate Program: Publisher Review
Publisher information for Modified GRF 1-29 (“CJC-1295 without DAC”). Review the exact product or preparation, service scope and permitted promotion before discussing a campaign. Advertiser identities and commercial terms remain private.
Identity and public scope
This entry preserves Modified GRF 1-29 and the requested “CJC-1295 without DAC” wording for identification. It is not merged with the with-DAC entry. A marketing alias does not substitute for precise product documentation.
What publishers should establish
- Exact substance identity rather than the alias alone
- Clear separation from CJC-1295 with DAC
- Current preparation-specific eligibility and approved wording
What stays private
The advertiser brief must identify the actual product or service, eligible markets, permitted content and payable event. No private advertiser, payout, creative asset or tracking link is disclosed here.
A familiar substance name or a related approved product is not a substitute for the current brief.
Before creating content
Keep informational coverage separate from promotion. Verify exact names and preparation details, cite current primary sources for status statements, and do not infer an indication, route or outcome from a directory entry.
No dosing, stacking, administration or blend-formula instructions are provided. Research reporting and a private publisher inquiry do not establish treatment availability.
Modified GRF 1-29 publisher questions
What is this Modified GRF 1-29 affiliate program page?
It is publisher information about Modified GRF 1-29 (“CJC-1295 without DAC”). It supports preparation-specific review before any campaign is promoted.
Does this Modified GRF 1-29 page confirm campaign eligibility?
No blanket eligibility is established by the page. The exact product, preparation, service and current advertiser permissions must be reviewed privately.
Which name or formulation should a publisher use?
This entry preserves Modified GRF 1-29 and the requested “CJC-1295 without DAC” wording for identification. It is not merged with the with-DAC entry. A marketing alias does not substitute for precise product documentation.
Where are advertiser details and campaign terms reviewed?
Advertiser identities, payouts, approved creative, traffic permissions and tracking links are handled through the private publisher process.
Where can publishers apply for permitted telehealth programs?
Use MarketHealth Telehealth Publishers to describe your audience and proposed channels. An inquiry does not authorize promotion or establish access to an investigational product.
Status reference reviewed October 15, 2026: Official source. The reference provides context; it does not establish a MarketHealth campaign.
Related publisher information
Review private publisher requirements
Use the publisher application to discuss programs that meet current requirements. A public topic listing does not authorize an investigational or otherwise impermissible campaign.
Review private publisher access